Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 5.1% - Here's What Happened

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price shot up 5.1% during trading on Monday . The company traded as high as $6.95 and last traded at $6.81. 1,852,293 shares changed hands during trading, a decline of 67% from the average session volume of 5,697,418 shares. The stock had previously closed at $6.48.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on RXRX. KeyCorp cut their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, July 11th. Jefferies Financial Group cut their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a research note on Tuesday, September 3rd. Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC cut their price objective on Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating on the stock in a research report on Wednesday, September 4th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $9.40.

Recursion Pharmaceuticals Stock Performance

The company has a market capitalization of $1.93 billion, a P/E ratio of -4.24 and a beta of 0.80. The company's 50 day moving average is $6.71 and its 200-day moving average is $7.68. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. During the same period in the prior year, the business posted ($0.38) EPS. Recursion Pharmaceuticals's revenue for the quarter was up 30.9% on a year-over-year basis. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares of the company's stock, valued at $3,288,380.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm's stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $6.31, for a total transaction of $37,860.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares in the company, valued at approximately $3,288,380.78. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher Gibson sold 20,000 shares of the company's stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 201,682 shares of company stock valued at $1,322,013. 15.75% of the stock is currently owned by corporate insiders.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC bought a new position in shares of Recursion Pharmaceuticals during the second quarter valued at $5,769,000. Capstone Investment Advisors LLC bought a new position in Recursion Pharmaceuticals during the 1st quarter valued at about $161,000. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 6,439.6% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company's stock valued at $1,274,000 after acquiring an additional 167,302 shares during the last quarter. Scientech Research LLC bought a new stake in shares of Recursion Pharmaceuticals in the second quarter worth approximately $1,052,000. Finally, Ghisallo Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $8,250,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.